|
Change History
Message: [Medicine][BioMedical] The First Domestic Leukemia New Drug in Taiwan Transferred by ITRI
Changed By: techman
Change Date: February 24, 2011 12:10AM
[Medicine][BioMedical] The First Domestic Leukemia New Drug in Taiwan Transferred by ITRI
Change Date: February 24, 2011 12:10AM
[Medicine][BioMedical] The First Domestic Leukemia New Drug in Taiwan Transferred by ITRI
[Medicine][BioMedical] The First Domestic Leukemia New Drug in Taiwan Transferred by ITRI (<a href=http://mepopedia.com/forum/read.php?127,10789>Chinese Version</a>)
<i>BCC</i> (2011/02/22) ITRI and Wan Fang Hospital together developed the first domestically made leukemia target drug candidate, which was transferred to local biomedical manufacturer on February 22 and was expected to enter the market soonest in five years. In the future, the AML (acute myeloid leukemia ) patients will have one more drug option.
The development of this anti-cancer drug candidate, ITRI-260 , jointly by ITRI and Wan Fang Hospital was supported under the TDPs, DoIT, MoEA ((Industrial) Technology Development Programs of the Department of Industrial Technology, Ministry of Economic Affairs). This was the first independently made and patent-owned anti-cancer drug in Taiwan, which makes Taiwan step out of the stage as mere generic drugs and API (active pharmaceutical ingredients) provider. The achievement was regarded as an important milestone of the biotechnological industry in Taiwan.
The anti-cancer target drug candidate aims at curing AML, namely, the blood cancer. Chemotherapy is the major option for AML now, but about 60-80% of the patients under chemotherapy suffered from relapse in two years after the treatment. ITRI's ITRI-260 was low-toxic and highly effective. The transferred technologies will be realized as new drugs soonest in five years, and a wider range of application including lung cancer and thyroid cancer is also anticipated.
Reference:
<a href=http://www.bcc.com.tw/news/newsview.asp?cde=1428433>BCC 2011/02/22</a> (Chinese)
<i>BCC</i> (2011/02/22) ITRI and Wan Fang Hospital together developed the first domestically made leukemia target drug candidate, which was transferred to local biomedical manufacturer on February 22 and was expected to enter the market soonest in five years. In the future, the AML (acute myeloid leukemia ) patients will have one more drug option.
The development of this anti-cancer drug candidate, ITRI-260 , jointly by ITRI and Wan Fang Hospital was supported under the TDPs, DoIT, MoEA ((Industrial) Technology Development Programs of the Department of Industrial Technology, Ministry of Economic Affairs). This was the first independently made and patent-owned anti-cancer drug in Taiwan, which makes Taiwan step out of the stage as mere generic drugs and API (active pharmaceutical ingredients) provider. The achievement was regarded as an important milestone of the biotechnological industry in Taiwan.
The anti-cancer target drug candidate aims at curing AML, namely, the blood cancer. Chemotherapy is the major option for AML now, but about 60-80% of the patients under chemotherapy suffered from relapse in two years after the treatment. ITRI's ITRI-260 was low-toxic and highly effective. The transferred technologies will be realized as new drugs soonest in five years, and a wider range of application including lung cancer and thyroid cancer is also anticipated.
Reference:
<a href=http://www.bcc.com.tw/news/newsview.asp?cde=1428433>BCC 2011/02/22</a> (Chinese)
Changed By: techman
Change Date: February 23, 2011 03:33PM
[Medicine][BioMedical] The First Domestic Leukemia New Drug in Taiwan Transferred by ITRI
Change Date: February 23, 2011 03:33PM
[Medicine][BioMedical] The First Domestic Leukemia New Drug in Taiwan Transferred by ITRI
[Medicine][BioMedical] The First Domestic Leukemia New Drug in Taiwan Transferred by ITRI (<a href=http://mepopedia.com/forum/read.php?127,10789>Chinese Version</a>)
<i>BCC</i> (2011/02/22) ITRI and Wan Fang Hospital together developed the first domestically made leukemia target drug candidate, which was transferred to local biomedical manufacturer on February 22 and was expected to enter the market soonest in five years. In the future, the AML (acute myeloid leukemia ) patients will have one more drug option.
The development of this anti-cancer drug candidate, ITRI-260 jointly by ITRI and Wan Fang Hospital was supported under the TDPs, DoIT, MoEA ((Industrial) Technology Development Programs of the Department of Industrial Technology, Ministry of Economic Affairs). This was the first independently made and patent-owned anti-cancer drug in Taiwan, which makes Taiwan step out of the stage as mere generic drugs and API (active pharmaceutical ingredients) provider. The achievement was regarded as an important milestone of the biotechnological industry in Taiwan.
The anti-cancer target drug candidate aims at curing AML, namely, the blood cancer. Chemotherapy is the major option for AML now, but about 60-80% of the patients under chemotherapy suffered from relapse in two years after the treatment. ITRI's ITRI-260 was low-toxic and highly effective. The transferred technologies will be realized as new drugs soonest in five years, and a wider range of application including lung cancer and thyroid cancer is also anticipated.
Reference:
<a href=http://www.bcc.com.tw/news/newsview.asp?cde=1428433>BCC 2011/02/22</a> (Chinese)
<i>BCC</i> (2011/02/22) ITRI and Wan Fang Hospital together developed the first domestically made leukemia target drug candidate, which was transferred to local biomedical manufacturer on February 22 and was expected to enter the market soonest in five years. In the future, the AML (acute myeloid leukemia ) patients will have one more drug option.
The development of this anti-cancer drug candidate, ITRI-260 jointly by ITRI and Wan Fang Hospital was supported under the TDPs, DoIT, MoEA ((Industrial) Technology Development Programs of the Department of Industrial Technology, Ministry of Economic Affairs). This was the first independently made and patent-owned anti-cancer drug in Taiwan, which makes Taiwan step out of the stage as mere generic drugs and API (active pharmaceutical ingredients) provider. The achievement was regarded as an important milestone of the biotechnological industry in Taiwan.
The anti-cancer target drug candidate aims at curing AML, namely, the blood cancer. Chemotherapy is the major option for AML now, but about 60-80% of the patients under chemotherapy suffered from relapse in two years after the treatment. ITRI's ITRI-260 was low-toxic and highly effective. The transferred technologies will be realized as new drugs soonest in five years, and a wider range of application including lung cancer and thyroid cancer is also anticipated.
Reference:
<a href=http://www.bcc.com.tw/news/newsview.asp?cde=1428433>BCC 2011/02/22</a> (Chinese)
Changed By: techman
Change Date: February 23, 2011 03:32PM
[Medicine][BioMedical] The First Domestic Leukemia New Drug in Taiwan Transferred by ITRI
Change Date: February 23, 2011 03:32PM
[Medicine][BioMedical] The First Domestic Leukemia New Drug in Taiwan Transferred by ITRI
[Medicine][BioMedical] The First Domestic Leukemia New Drug in Taiwan Transferred by ITRI (<a href=>Chinese Version</a>)
<i>BCC</i> (2011/02/22) ITRI and Wan Fang Hospital together developed the first domestically made leukemia target drug candidate, which was transferred to local biomedical manufacturer on February 22 and was expected to enter the market soonest in five years. In the future, the AML (acute myeloid leukemia ) patients will have one more drug option.
The development of this anti-cancer drug candidate, ITRI-260 jointly by ITRI and Wan Fang Hospital was supported under the TDPs, DoIT, MoEA ((Industrial) Technology Development Programs of the Department of Industrial Technology, Ministry of Economic Affairs). This was the first independently made and patent-owned anti-cancer drug in Taiwan, which makes Taiwan step out of the stage as mere generic drugs and API (active pharmaceutical ingredients) provider. The achievement was regarded as an important milestone of the biotechnological industry in Taiwan.
The anti-cancer target drug candidate aims at curing AML, namely, the blood cancer. Chemotherapy is the major option for AML now, but about 60-80% of the patients under chemotherapy suffered from relapse in two years after the treatment. ITRI's ITRI-260 was low-toxic and highly effective. The transferred technologies will be realized as new drugs soonest in five years, and a wider range of application including lung cancer and thyroid cancer is also anticipated.
Reference:
<a href=http://www.bcc.com.tw/news/newsview.asp?cde=1428433>BCC 2011/02/22</a> (Chinese)
<i>BCC</i> (2011/02/22) ITRI and Wan Fang Hospital together developed the first domestically made leukemia target drug candidate, which was transferred to local biomedical manufacturer on February 22 and was expected to enter the market soonest in five years. In the future, the AML (acute myeloid leukemia ) patients will have one more drug option.
The development of this anti-cancer drug candidate, ITRI-260 jointly by ITRI and Wan Fang Hospital was supported under the TDPs, DoIT, MoEA ((Industrial) Technology Development Programs of the Department of Industrial Technology, Ministry of Economic Affairs). This was the first independently made and patent-owned anti-cancer drug in Taiwan, which makes Taiwan step out of the stage as mere generic drugs and API (active pharmaceutical ingredients) provider. The achievement was regarded as an important milestone of the biotechnological industry in Taiwan.
The anti-cancer target drug candidate aims at curing AML, namely, the blood cancer. Chemotherapy is the major option for AML now, but about 60-80% of the patients under chemotherapy suffered from relapse in two years after the treatment. ITRI's ITRI-260 was low-toxic and highly effective. The transferred technologies will be realized as new drugs soonest in five years, and a wider range of application including lung cancer and thyroid cancer is also anticipated.
Reference:
<a href=http://www.bcc.com.tw/news/newsview.asp?cde=1428433>BCC 2011/02/22</a> (Chinese)
Original Message
雿: techmanDate: February 23, 2011 03:31PM
[Medicine][BioMedical] The First Domestic Leukemia New Drug Transferred by ITRI
[Medicine][BioMedical] The First Domestic Leukemia New Drug Transferred by ITRI (Chinese Version)
BCC (2011/02/22) ITRI and Wan Fang Hospital together developed the first domestically made leukemia target drug candidate, which was transferred to local biomedical manufacturer on February 22 and was expected to enter the market soonest in five years. In the future, the AML (acute myeloid leukemia ) patients will have one more drug option.
The development of this anti-cancer drug candidate, ITRI-260 jointly by ITRI and Wan Fang Hospital was supported under the TDPs, DoIT, MoEA ((Industrial) Technology Development Programs of the Department of Industrial Technology, Ministry of Economic Affairs). This was the first independently made and patent-owned anti-cancer drug in Taiwan, which makes Taiwan step out of the stage as mere generic drugs and API (active pharmaceutical ingredients) provider. The achievement was regarded as an important milestone of the biotechnological industry in Taiwan.
The anti-cancer target drug candidate aims at curing AML, namely, the blood cancer. Chemotherapy is the major option for AML now, but about 60-80% of the patients under chemotherapy suffered from relapse in two years after the treatment. ITRI's ITRI-260 was low-toxic and highly effective. The transferred technologies will be realized as new drugs soonest in five years, and a wider range of application including lung cancer and thyroid cancer is also anticipated.
Reference:
BCC 2011/02/22 (Chinese)
BCC (2011/02/22) ITRI and Wan Fang Hospital together developed the first domestically made leukemia target drug candidate, which was transferred to local biomedical manufacturer on February 22 and was expected to enter the market soonest in five years. In the future, the AML (acute myeloid leukemia ) patients will have one more drug option.
The development of this anti-cancer drug candidate, ITRI-260 jointly by ITRI and Wan Fang Hospital was supported under the TDPs, DoIT, MoEA ((Industrial) Technology Development Programs of the Department of Industrial Technology, Ministry of Economic Affairs). This was the first independently made and patent-owned anti-cancer drug in Taiwan, which makes Taiwan step out of the stage as mere generic drugs and API (active pharmaceutical ingredients) provider. The achievement was regarded as an important milestone of the biotechnological industry in Taiwan.
The anti-cancer target drug candidate aims at curing AML, namely, the blood cancer. Chemotherapy is the major option for AML now, but about 60-80% of the patients under chemotherapy suffered from relapse in two years after the treatment. ITRI's ITRI-260 was low-toxic and highly effective. The transferred technologies will be realized as new drugs soonest in five years, and a wider range of application including lung cancer and thyroid cancer is also anticipated.
Reference:
BCC 2011/02/22 (Chinese)
MEPO forum
is powered by Phorum.